Clinical trials: Mask
Sleep Apnea Syndromes
Amara View Benchmark Study
This randomized crossover, benchmark clinical trial aims to compare the Philips Amara View and ResMed AirFit F40 minimal contact full face masks on patient preference of mask attributes and usage parameters.
- Trial name
- NCT06535932
- Testing
- Amara View Minimal Contact Full Face Mask, F40 Minimal Contact Full Face Mask
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Retinitis Pigmentosa
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 6.0 million (6.0M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP.
- Trial name
- NCT06912633
- Testing
- human retinal progenitor cells, Mock injection
- Where
- 12 sites in United States
- Volunteers
- 31 people
- Sponsor
- jCyte, Inc
Dry Eye Disease
A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)
Evaluate the efficacy and safety of Lifitegrast in subjects with dry eye disease and a recent history of artificial tear use.
- Trial name
- OPUS-3 (NCT02284516)
- Testing
- Lifitegrast
- Where
- 41 sites in United States
- Volunteers
- 711 people
- Sponsor
- Shire
Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)
Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
Qlaris Phase 2 clinical study investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in combination with latanoprost in open-angle glaucoma (OAG) and/or ocular hypertension (OHT) patients.
- Conditions
- Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma
- Trial name
- NCT06249152
- Testing
- QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075%
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Qlaris Bio, Inc.
Ocular Hypertension, Open Angle-glaucoma
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
The primary objectives of this study are to compare the safety, tolerability, and mean change from baseline in diurnal intraocular pressure (IOP) of ONO-9054 30 µg/mL (0.003%) to latanoprost 0.005% following ocular instillation…
- Trial name
- NCT02083289
- Testing
- ONO-9054, Latanoprost
- Where
- 12 sites in United States
- Volunteers
- 123 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Dry Eye Disease
Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease
The purpose of this trial is to compare the effectiveness and safety of INS365 Ophthalmic Solution with placebo when applied topically in subjects with dry eye disease.
- Trial name
- NCT00404131
- Testing
- diquafosol tetrasodium (INS365) Ophthalmic Solution
- Volunteers
- 500 people
- Sponsor
- Merck Sharp & Dohme LLC
Allergic Conjunctivitis
Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis
The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis
- Trial name
- NCT00241319
- Testing
- R89674 (generic name not yet established)
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- Vistakon Pharmaceuticals
Dry Eye, Graft-versus-host-disease
Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease
The purpose of this Phase 1/2 study is to compare the safety and tolerability of four times a day (QID) dosing of a non-preserved topical ocular drop formulation of 10 vol/vol % and 30 vol/vol % of FD hPL to vehicle control eye…
- Conditions
- Dry Eye, Graft-versus-host-disease, Ocular Discomfort
- Trial name
- NCT03414645
- Testing
- CAM-101 10%, Vehicle Control, CAM-101 30%
- Where
- 6 sites in United States
- Volunteers
- 64 people
- Sponsor
- Cambium Bio Limited
Dry Eye
Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)
This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the treatment of Dry Eye Disease (DED). Half of participants will receive Brimonidine and half will receive ophthalmic buffered saline…
- Trial name
- NCT03785340
- Testing
- Brimonidine Tartrate
- Where
- 16 sites in United States
- Volunteers
- 252 people
- Sponsor
- Ocugen
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
This study is evaluating a new eye drop containing pregabalin (TB0001) as a potential treatment for people with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT07913074
- Testing
- Arm 1: TB0001 ophthalmic solution 0.9%, Arm 2: TB0001 ophthalmic solution 1.2%, TB0001 ophthalmic solution 1.5%
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Tavo Biotherapeutics
Dry Eye
Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)
Primary objectives To compare the efficacy of cenegermin vs vehicle in Schirmer I test (without anaesthesia) >10mm/5min at Week 4 by testing the superiority.
- Trial name
- NCT05133180
- Testing
- Oxervate, Vehicle
- Where
- 10 sites in United States, Italy
- Volunteers
- 104 people
- Sponsor
- Dompé Farmaceutici S.p.A
Wet Age-related Macular Degeneration
Efficacy and Safety of RC28-E Versus Aflibercept
This is a randomized, double-masked, multicenter study comparing the the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) versus aflibercept in patients…
- Trial name
- NCT05727397
- Testing
- RC28-E, Aflibercept
- Where
- China
- Volunteers
- 432 people
- Sponsor
- RemeGen Co., Ltd.
oGVHD, Ocular Graft Versus Host Disease
Study of d-MAPPS™ Ophthalmic Solution in Adults With Chronic Ocular Graft-Versus-Host Disease (oGVHD)
This is a Phase III, multicenter, randomized, double-masked, vehicle-controlled, parallel-group clinical trial designed to evaluate the efficacy, safety, and tolerability of d-MAPPS™ Ophthalmic Solution in adult subjects with…
- Trial name
- NCT07776210
- Testing
- d-MAPPS™ Ophthalmic Solution, Matching vehicle control
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Regenerative Ocular Immunobiologics LLC
Central Retinal Vein Occlusion
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).
- Trial name
- RAVEN (NCT03810313)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 120 sites in United States, Australia and 18 more
- Volunteers
- 493 people
- Sponsor
- Novartis Pharmaceuticals
Eyelash Hypotrichosis
Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% compared with vehicle in Japanese adults with hypotrichosis of the eyelashes.
- Trial name
- NCT01391273
- Testing
- bimatoprost solution 0.03%, bimatoprost vehicle solution
- Where
- Japan
- Volunteers
- 173 people
- Sponsor
- Allergan
Allergic Conjunctivitis
Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model
The purpose of this study was to assess the safety and efficacy of AL-4943A ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.
- Trial name
- NCT01479374
- Testing
- AL-4943A ophthalmic solution, AL-4943A vehicle, Olopatadine hydrochloride ophthalmic solution, 0.2%
- Volunteers
- 397 people
- Sponsor
- Alcon Research
Amblyopia
CURESIGHT BINOCULAR AMBLYOPIA TREATMENT STUDY
Screening A child is considered for the study after undergoing a standard of care and study specific eye examinations (by a study investigator as part of standard of care) that identifies amblyopia appearing to meet the…
- Trial name
- NCT04785690
- Testing
- CureSight, Patching
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- NovaSight
Dry Eye Disease
Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops
The primary objective is to evaluate the tolerability and efficacy of CWT-f-002 lubricant eye drops in the treatment of the signs and symptoms of dry eye disease.
- Trial name
- NCT05660681
- Testing
- glycerin 0.7%/PEG 400 0.3%, polyethylene glycol 400 0.4%/propylene glycol 0.3%
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Calm Water Therapeutics LLC
Healthy Subjects
A Study to Explore the Physiological Impact of AIR+ KN95 Masks on Children
The primary objective is to evaluate the physiological impact of AIR+ KN95 Masks on end-tidal carbon dioxide (ETCO2) of children aged 7 to 14 years of age.
- Trial name
- NCT07037381
- Testing
- KN95 mask
- Where
- Singapore
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Innosparks Pte Ltd.
Angle-closure Glaucoma
Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)
The purpose of this study is to demonstrate that the Intraocular Pressure (IOP) lowering efficacy of Travoprost Ophthalmic Solution 0.004% is superior to that of Pilocarpine 1% in patients with chronic angle-closure glaucoma…
- Trial name
- NCT00762645
- Testing
- Travoprost 0.004% (Travatan), Pilocarpine 1%
- Volunteers
- 30 people
- Sponsor
- Alcon Research
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.